
Oncology Times Broadcast News with the Audio Journal of Oncology – February 2009
Mary Eapen Peter Goodwin interviews more speakers from the 50th American Society of Hematology Annual Meeting, San Francisco, December 6-9, 2008 IN THIS EDITION: Greater Role for Umbilical Cord Blood

Mary Eapen
Peter Goodwin interviews more speakers from the 50th American Society of Hematology Annual Meeting, San Francisco, December 6-9, 2008
IN THIS EDITION:Greater Role for Umbilical Cord Blood in Adult TransplantsMary Eapen, Medical College of Wisconsin, Milwaukee
COMMENT:Armand Keating, University of Toronto
Ex Vivo Expansion Of Cord Blood Derived Progenitor Cells: Patient Transplant DataColleen Delaney, Fred Hutchinson Cancer Research Center, Seattle
COMMENT:Armand Keating
Erythropoiesis Stimulating Agents in Cancer Patients: Meta-Analysis Mortality FindingsJulia Bohlius, University of Bern
ON BEHALF OF: Erythropoiesis Stimulating Agents Individual Patient Data (EPO IPD) Meta-Analysis Collaborative Group
COMMENTS:Linda Burns, University of Minnesota, MinneapolisGeorge Canellos, Dana-Farber Cancer Institute, Boston
Imatinib: Durable Responses And Survival in Chronic Myeloid Leukemia: 7-Year IRIS Study Results; Can Imatinib Be Stopped?Stephen O’Brien, Newcastle University, England

Armand Keating

Colleen Delaney

Julia Bohlius

George Canellos

Stephen O’Brien
Tags
More from ASH 2008
All 1 interviewsThis is the last of the 1 ASH 2008 interviews. See them all.
Related Episodes

Li Zhang MD; ESMO 2025: Patients with EGFR-mutated Lung Cancer Progressing After Tyrosine Kinase Therapy Live Longer with Sacituzumab Tirumotecan Therapy
Antibody Drug Conjugate Prolongs Life in NSCLC refractory to EGFR TKI Therapy

Rebecca Dent MD: ESMO Previous Highlights: Neo-Adjuvant Therapy for Triple Negative Breast Cancer, Checkpoint Inhibition, AI, Cancer Vaccines, and More ……
Rebecca Dent surveys the most recent ESMO Annual Meeting to prepare our thoughts for the ESMO 2025 meeting

Breast Cancer: Combined Risk Assessment Prompts Treatment De-Escalation
BARCELONA—Not only was breast conserving therapy safer than mastectomy for most low-risk patients in the large randomized EORTC 10041/BIG 03-04 MINDACT trial reported at the 2018 European Breast Cance